D&D Pharmatech is set to unveil preclinical study results for its obesity drug candidate 'DD18' for the first time at a global obesity-specialized academic conference, but its share price showed weakness on the 25th.

As of the day, D&D Pharmatech shares were trading at 55,100 won, down 2,100 won from the previous trading day. This represents a decline of about 3.67% from the prior day's closing price of 57,200 won.

■ DD18 Preclinical Results to Be Revealed for First Time at ObesityWeek 2026

D&D Pharmatech announced that it will participate in 'ObesityWeek 2026,' to be held from November 14 to 17 in Washington, D.C., USA, where it will present preclinical study results for DD18, a UCN2 analog candidate.

ObesityWeek is a specialized obesity conference attended by basic science researchers and clinicians in the obesity field, as well as officials from global pharmaceutical and biotech companies. As the obesity treatment market has grown rapidly, research results on candidates with new mechanisms of action have emerged as a major focus of interest.

D&D Pharmatech plans to unveil the preclinical study results of DD18, a CRFR2 (Corticotropin-Releasing Factor Receptor 2)-selective UCN2 analog, for the first time at a poster session during the conference.

■ GLP-1-Centered Market: Differentiation Through a 'New Mechanism' Is Key

With the global obesity treatment market growing rapidly around GLP-1-based drugs, the key question is whether candidates with new mechanisms of action can demonstrate differentiation from existing treatments. The market will also be watching how much DD18's preclinical data support its future development potential.

However, the share price declined on the day, separate from the announced research results. Biotech stock prices can move in directions contrary to actual news, depending not only on drug development expectations but also on the degree to which expectations are already priced in, short-term supply and demand, and changes in overall market risk appetite.

[This article was written with AI assistance. This article is for informational purposes only and does not recommend buying or selling any specific stock. Volatility can be high, and a change in margin requirements does not imply a rise in share price, so investment decisions and responsibility rest with the investor.]